Azenta

AZTA · NASDAQ

$35.73+$0.89 (+2.55%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $34.84

AZTA analyst rating

BuyConsensus of 5 analysts over the last 12 months. 80% rate it a buy.

Strong buy0
Buy4
Hold1
Underperform0
Sell0

12-month price target · 8 analysts

Average $36.38 (+1.8% upside)

Low: $33.33
Now: $35.73
High: $42.00

Upgrades and downgrades

The latest rating actions, newest first

AZTA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Needham	Sep 14, 2026	Maintains	Buy	$37.00	39%
Evercore ISI Group	Aug 6, 2026	Maintains	Outperform	$28.00 → $35.00	52%
Needham	Aug 5, 2026	Maintains	Buy	$33.00 → $37.00	39%
Needham	May 6, 2026	Maintains	Buy	$44.00 → $33.00	39%
Evercore ISI Group	Apr 6, 2026	Maintains	Outperform	$45.00 → $35.00	52%
Needham	Mar 17, 2026	Maintains	Buy	$44.00	39%
Evercore ISI Group	Feb 5, 2026	Maintains	Outperform	$50.00 → $45.00	52%
Jefferies	Feb 4, 2026	Maintains	Buy	$42.00 → $40.00	67%
Needham	Feb 4, 2026	Maintains	Buy	$44.00	39%
TD Cowen	Jan 8, 2026	Maintains	Hold	$35.00 → $39.00	68%

The case for and against

Updated Oct 21, 2026

Bull case

Azenta is positioned favorably because its Sample Management Solutions franchise should continue to benefit from outsourcing trends, while Multiomics offers an additional growth lever if execution improves. Management and the analyst view both center on revenue growth improving into the mid-single digits, alongside continued margin expansion that could drive stronger adjusted EBITDA and earnings over the next few years. Even after F2Q26 revenue and adjusted EBITDA missed consensus due to softer North America Multiomics and constrained capital demand, the company’s balance sheet and free cash flow profile are seen as limiting downside while leaving room for faster profitability.

Bear case

Azenta is facing a clear fundamental slowdown as both segments missed consensus, with revenue of $145M, adjusted EBITDA of $8M versus $17M expected, and adjusted EPS of ($0.04) versus $0.12, while organic revenue fell 3% year over year. Management also cut FY26 organic revenue growth guidance to (2%)-1% and lowered adjusted EBITDA margin guidance to down 125-0 bps, implying roughly 10%-11%, reflecting weaker demand in automated and cryo stores and softer North America Multiomics activity. The outlook stays negative because guidance was reduced after a one-time $3M consulting expense, the long-range plan was pushed from FY28 to FY29, and lowered FY26E/FY27E revenue and EPS estimates signal limited near-term operating leverage.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.